FULL GENOMIC ANALYSIS OF ANAVEX ? 2-73 PHASE 2A ALZHEIMER’S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH

Harald Hampel; Mohammad Afshar; Frédéric Parmentier; Coralie Williams; Adrien Etcheto; Federico Goodsaid; Emmanuel O. Fadiran; Christopher U. Missling

首页> 外文期刊>Alzheimer’s & dementia: the journal of the Alzheimer’s Association >FULL GENOMIC ANALYSIS OF ANAVEX ? 2-73 PHASE 2A ALZHEIMER’S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH

【24h】

FULL GENOMIC ANALYSIS OF ANAVEX ? 2-73 PHASE 2A ALZHEIMER’S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH

机译：Anavex的全基因组分析？ 2-73阶段2a Alzheimer的疾病研究识别生物标志物，使有针对性的治疗和精密药物方法

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Alzheimer’s & dementia: the journal of the Alzheimer’s Association》 |2018年第7期|共2页
作者
Harald Hampel; Mohammad Afshar; Frédéric Parmentier; Coralie Williams; Adrien Etcheto; Federico Goodsaid; Emmanuel O. Fadiran; Christopher U. Missling;
展开▼
作者单位

Sorbonne University;

Ariana Pharma;

Ariana Pharma;

Ariana Pharma;

Ariana Pharma;

Regulatory Pathfinders LLC;

Anavex Life Sciences Corp;

Anavex Life Sciences Corp;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. FULL GENOMIC ANALYSIS OF ANAVEX ? 2-73 PHASE 2A ALZHEIMER’S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH [J] . Harald Hampel, Mohammad Afshar, Frédéric Parmentier, Alzheimer’s & dementia: the journal of the Alzheimer’s Association . 2018,第7期

机译：Anavex的全基因组分析？ 2-73阶段2a Alzheimer的疾病研究识别生物标志物，使有针对性的治疗和精密药物方法
2. SIGMA-1 RECEPTOR TARGET OCCUPANCY STUDY WITH DYNAMIC PET SCAN ANALYSIS OF ANAVEX ? 2-73: A CLINICAL CANDIDATE FOR NEURODEGENERATIVE AND NEURODEVELOPMENTAL DISEASES [J] . Samantha T. Reyes, Scarlett G. Guo, Jessa B. Castillo, Alzheimer’s & dementia: the journal of the Alzheimer’s Association . 2018,第7期

机译：Sigma-1受体靶向占用研究与Anavex的动态宠物扫描分析？ 2-73：神经变性和神经发育疾病的临床候选者
3. Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology [J] . Harald Hampel, Edward J. Goetzl, Dimitrios Kapogiannis, Frontiers in Pharmacology . 2019,第6期

机译：生物标志物-药物和液体活检共同开发用于疾病分期和靶向治疗：阿尔茨海默氏症精确医学和药理学的基石
4. GWAS with AHP based SNP prioritization approach to identify SNP biomarkers for Alzheimer's disease [C] . Kadioglu Onat, Ustunkar Gurkan, Son Yesim Aydin Health Informatics and Bioinformatics (HIBIT), 2012 7th International Symposium on . 2012

机译：GWAS与基于AHP的SNP优先排序方法一起确定阿尔茨海默氏病的SNP生物标志物
5. Development of micro immunosensors to study genomic and proteomic biomarkers related to cancer and Alzheimer's disease [D] . Prabhulkar, Shradha 2011

机译：微型免疫传感器的开发，用于研究与癌症和阿尔茨海默氏病有关的基因组和蛋白质组生物标记
6. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimers disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study [O] . Harald Hampel, Coralie Williams, Adrien Etcheto, 2020

机译：使用人工智能的精密医学框架用于识别和确认对阿尔茨海默氏病治疗反应的基因组生物标志物：布拉卡米碱（ANAVEX2-73）2a期临床研究的分析
7. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study [O] . Harald Hampel, Coralie Williams, Adrien Etcheto, 2020

机译：一种使用人工智能的精密药框架，用于鉴定和确认对阿尔茨海默病治疗的应对基因组生物标志物：分析Blarcamesine（Anavex2-73）2A期临床研究

FULL GENOMIC ANALYSIS OF ANAVEX ? 2-73 PHASE 2A ALZHEIMER’S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH

著录项

引文网络

相似文献

相关主题

期刊订阅